Bacterial Infections Clinical Trial
Official title:
A Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
The primary purpose of the study is to evaluate whether weekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in participants with hypogammaglobulinemia (HGG) associated with B-cell chronic lymphocytic leukemia (CLL) in comparison to the Placebo plus SMT group.
Status | Recruiting |
Enrollment | 386 |
Est. completion date | June 2026 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants =18 years of age at screening - Participants with documented and confirmed diagnosis of B-cell CLL according to International Workshop on CLL (iwCLL) criteria. - Participants with hypogammaglobulinemia with immunoglobulin G (IgG) levels <4 grams per liter (g/L) - Participants with RAI staging of intermediate (1 and 2) or high (3 and 4) as documented in the participant's medical history. - Participants with documented history of at least one severe bacterial infection or recurrent bacterial infections (that is., = 3 infections) within 12 months before the screening visit. Severe bacterial infections = Grade 3 (as defined by Common Terminology Criteria for Adverse Events [CTCAE] Grades). Exclusion Criteria: - Participants with documented history of hematopoietic stem cell transplant. - Participants currently receiving immunoglobulin replacement therapy (IgRT) or have received IgG replacement treatment (i.e., prior immune globulin replacement therapy) within 6 months before the screening visit. - Participants with active infections or receiving therapeutic or prophylactic antibiotic treatment at time of screening visit. Specific supportive anti-infective prophylactic defined in the CLL National Comprehensive Cancer Network (NCCN) or iwCLL guidelines or recommended in the updated labelling of specific antileukemic medicines used during the participation in the trial is allowed. - Participants with active second malignancies. - Participants with known primary immunodeficiency (PI). - Participants with a life expectancy less than 1.5 years. - Participants with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the subject at undue medical risk. - Participants have had a known serious adverse reaction (AR) to immunoglobulin or any anaphylactic reaction to blood or any blood-derived product. - Participants have a history of blistering skin disease, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study based upon the Investigator's discretion. - Participants have known Selective Immunoglobulin A (IgA) Deficiency (with or without antibodies to IgA) (Note: exclusion is for the specific diagnostic entity. It does not exclude other forms of humoral primary immunodeficiency which have decreased IgA in addition to decreased IgG requiring IgG replacement). - Participants with severe known kidney disease [as defined by estimated glomerular filtration rate [eGFR] less than (<) 30 milliliter (mL)/min/1.73 square meter (m2)] as determined by the Principal Investigator. - Participants that have liver enzyme levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gammaglutamyl transferase [GGT], or lactate dehydrogenase [LDH]) greater than 3 times the upper limit of normal (ULN) at the Screening Visit as defined by the testing laboratory. - Participants have a history (either 1 episode within the year prior to the Screening Visit or 2 previous episodes over a lifetime) of or current diagnosis of thromboembolism (example, myocardial infarction, cerebrovascular accident, or transient ischemic attack) or deep venous thrombosis. - Participants are currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonists, nonvitamin K antagonist oral anticoagulants [example, dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], and parenteral anticoagulants [example, fondaparinux]). - Participants currently have a known hyperviscosity syndrome or hypercoagulable states. - Participants have a known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection. - Participants with non-controlled arterial hypertension (systolic blood pressure [SBP] more than (>)140 millimeters of mercury (mmHg) and/or diastolic blood pressure [DBP] >90 mmHg), and/or a heart rate (HR) >100 bpm. - Participants with known substance or prescription drug abuse within 12 months before the Screening Visit. - Participants have participated in another clinical trial within 30 days prior to screening (observational studies without investigative treatments [non-interventional] are permitted). |
Country | Name | City | State |
---|---|---|---|
Bulgaria | "University multiprofile hospital for active treatment - Burgas" AD, Internal diseases II level, clinical hematology I level | Burgas | |
Bulgaria | "Medical Center Leo Clinic" EOOD, consulting room 15 | Plovdiv | |
Bulgaria | "Complex oncology center - Ruse" EOOD, Department - medical oncology II level | Ruse | |
Bulgaria | """Specialized Hospital for active treatment of hematological diseases"" EAD, First department clinical hematology to clinic on clinical hematology - clinical hematology III level" | Sofia | |
Bulgaria | "Medical Center "Sirtuin"" Ltd, consulting room 7 | Sofia | |
Bulgaria | "Specialized Hospital for active treatment of hematological diseases" EAD, Second department clinical hematology to clinic on clinical hematology - clinical hematology III level | Sofia | |
Bulgaria | "University First multiprofile hospital for active treatment - Sofia "St. Joan Krastitel"" EAD, Third Department of Internal Diseases | Sofia | |
Bulgaria | "University multiprofile hospital for active treatment "Sv. Ivan Rilski"" EAD, Department of clinical hematology at Clinical Hematology Clinic - clinical hematology III level | Sofia | |
Bulgaria | "University multiprofile hospital for active treatment and emergency medicine "N.I. Pirogov"" EAD, Internal diseases - internal diseases III level | Sofia | |
Poland | Wojewodzki Szpital Specjalistyczny w Legnicy, Oddzial Hematologii | Legnica | Dolnoslaskie |
Poland | Wojewodzki Szpital Specjalistyczny imienia Janusza Korczaka w Slupsku Sp. z o.o., Oddzial Hematologii | Slupsk | Pomorskie |
Poland | Centrum Medyczne MICS Torun | Torun | Kujawsko-pomorskie |
Romania | Onco Card Srl | Brasov | RO |
Romania | Spitalul Clinic Coltea | Bucuresti | RO |
Romania | IOCN | Cluj-Napoca | RO |
Romania | Spitalul Clinic Municipal de Urgenta Timisoara | Timisoara | RO |
Serbia | "University Clinical Center of Serbia, Clinic of Hematology" | Belgrade | |
Serbia | "University Clinical Center Kragujevac, Clinic of Hematology" | Kragujevac | |
Serbia | "University Clinical Center Nis, Clinic for Hematology, Alergology and Clinical Immunology " | Nis | |
Serbia | "Oncology Institute of Vojvodina, Clinic for Internal Oncology " | Sremska Kamenica | |
United States | Gabrail Cancer and Research Center | Canton | Ohio |
United States | Optimed Research, LLC | Columbus | Ohio |
United States | Valley Cancer Associates | Harlingen | Texas |
United States | JD Medical Group LLC | Miami | Florida |
United States | Allergy and Clinical Immunology Associates | Pittsburgh | Pennsylvania |
United States | Carolina Blood and Cancer Care | Rockville | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Grifols Therapeutics LLC |
United States, Bulgaria, Poland, Romania, Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Annual Rate of Major Bacterial Infections per Year | Up to Week 53 | ||
Secondary | Time to First Onset of Major Bacterial Infection | Up to Week 53 | ||
Secondary | Percentage of Participants who Experience Major Bacterial Infections | Up to Week 53 | ||
Secondary | Rate of all Bacterial Infections Determined by the Investigator | Up to Week 53 | ||
Secondary | Time to First Onset of Non-Major Bacterial Infections | Up to Week 53 | ||
Secondary | Percentage of Participants who Experience Bacterial Infections | Up to Week 53 | ||
Secondary | Number of Days on Which Participants Were on Antibiotics | Up to Week 53 | ||
Secondary | Number of Hospitalizations due to any Infections | Up to Week 53 | ||
Secondary | Duration of Hospitalizations due to any Infections | Up to Week 53 | ||
Secondary | Number of Hospitalizations due to Major Bacterial Infections | Up to Week 53 | ||
Secondary | Duration of Hospitalizations due to Major Bacterial Infections | Up to Week 53 | ||
Secondary | Rate of all Infections as Determined by the Investigator | Up to Week 53 | ||
Secondary | Number of Participants with Validated Infections | Up to Week 53 | ||
Secondary | Time to First Onset of any Infection | Up to Week 53 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |